Document is current
Any future updates will be listed below
-
Authors
Dreyfuss, Jonathan M. https://orcid.org/0000-0001-7242-3991
Djordjilović, Vera https://orcid.org/0000-0002-7670-3111
Pan, Hui https://orcid.org/0000-0001-5748-7217
Bussberg, Valerie
MacDonald, Allison M.
Narain, Niven R.
Kiebish, Michael A.
Blüher, Matthias https://orcid.org/0000-0003-0208-2065
Tseng, Yu-Hua https://orcid.org/0000-0003-2053-9559
Lynes, Matthew D. https://orcid.org/0000-0003-0746-0854
-
Funding
Funding for this research was provided by:
United States Department of Defense | U.S. Army (W81XWH-17-1-0428)
- License Information
-
More Information
Article History
Received: 11 October 2023
Accepted: 29 July 2024
First Online: 14 August 2024
Competing interests
: The authors declare the following competing interests: AMM, MAK, NRN, and VB are and/or were employees of BPGbio Inc (formerly Berg LLC). MB received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Pfizer, and Sanofi. MDL and Y-HT are the inventors of US Patent 11,433,042, “Methods and compositions for treating metabolic disorders,” related to 12,13-diHOME. All other authors declare no competing interests.
